Project Grant R56HL171301
Award Date
9/17/24
Completion Date
8/31/25
Dollars Obligated
$765K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $685,884 to the University of North Carolina at Chapel Hill to conduct research on the regulation of coagulation and thrombosis by C1 inhibitor. The research aims to elucidate the molecular mechanisms by which endogenous C1 inhibitor regulates coagulation and venous thrombosis, evaluate the impact of C1 inhibitor deficiency on coagulation...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to characterize the role of Factor XII (FXII) in the thrombo-inflammatory complications of sickle cell disease (SCD). The $1,449,454 award to the University of North Carolina at Chapel Hill (UNC-CH) will fund research to: 1) identify disease-specific triggers of FXII activation, 2) characterize FXII effects on neutrophil...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $420,600 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Colorado-Denver. The grant's objective is to design elastic hydrogel microparticles as a platform to measure key elements of platelet function, including adhesion, activation, aggregation, and contraction. This innovative "lab-on-a-particle" approach aims to improve the reliability and reproducibility of platelet function...
This Project Grant award of $601,169 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by the University of Virginia to investigate the molecular basis for the progression of myeloproliferative neoplasms (MPNs), a group of hematologic malignancies characterized by overproduction of myeloid cells. The research aims to elucidate how the JAK2V617F mutation and deficiencies in the PTPN1 tumor suppressor gene cooperate to promote...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $767,077 to the University of North Carolina at Chapel Hill to validate and extend a platform technology for the delivery of protein-based drugs, with a focus on thrombolytic enzymes. The research aims to develop a biocompatible drug delivery system that can leverage the circulatory system as a natural drug depot, release the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $116,278 to the University of South Florida to investigate the role of the plasminogen activator (PA) pathway in lymphatic malformations. The key research activities include: Assessing the expression of key PA enzymes and utilizing in vitro zymography to evaluate matrix metalloproteinase (MMP) activation related to lymphatic valve defects...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $445,000 to The Children's Hospital of Philadelphia to conduct research on the role of neutrophil extracellular traps (NETs) in thromboinflammatory diseases. The research aims to: 1) characterize the role of NETs in immune homeostasis, 2) define the mechanism by which platelet factor 4 (PF4) and an Fc-modified anti-PF4 antibody...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,419,308 to the University of Pittsburgh to investigate the mechanisms linking persistent DNA damage to the upregulation of NLRP12 and the functional links between persistent DNA damage and NLRP12 in aging hematopoiesis. The award period is from Sep 17, 2024 to Aug 31, 2025. The research aims to elucidate a novel interplay between...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $465,000 in funding to Bloodworks, a non-profit organization based in Seattle, WA. The award supports research into the mechanisms by which chronic inflammation disrupts hemostatic function in sickle cell disease (SCD). Specifically, the project aims to investigate how TNF-driven inflammation in SCD blocks autophagy and mitophagy in...
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $161,922 to the Albert Einstein College of Medicine to elucidate the interplay between DDX41 and CUX1 mutations and their impact on hematopoiesis. The research will utilize zebrafish models and human induced pluripotent stem cells (iPSCs) to characterize changes in hematopoietic stem and progenitor cells, as well as differentiated progeny, under these...